Use of genetic testing enabled the detection of hereditary angioedema (HAE) in a previously misdiagnosed woman, found to be…
Articles by José Lopes, PhD
The unique mode each specific compound binds to and blocks the enzyme plasma kallikrein could lead to the development of…
Daily treatment with BCX7353, an investigative oral inhibitor of plasma kallikrein by BioCryst Pharmaceuticals, was well-tolerated and lowered attack rates in…
Using under-the-skin delivery of a C1-inhibitor (C1-INH) formulation in patients with hereditary angioedema with C1 inhibitor deficiency (C1-INH-HAE) decreased…
An abnormally short form of the clotting protein factor XII (FXII), caused by specific mutations in its gene, may lead…
Delays between symptom onset and diagnosis of hereditary angioedema (HAE) types 1 and 2 have been decreasing, according to…
The Committee for Medicinal Products for Human Use (CHMP), an arm of the European Medicines Agency (EMA), favors granting marketing…
The oral treatment candidate BCX7353 eases hereditary angioedema (HAE) attacks, reduces the occurrence of symptoms, and helps decrease the…
Treatment of hereditary angioedema (HAE) with C1-esterase inhibitors (C1-INH) provides efficient relief of acute attacks across different locations…
Patients with hereditary angioedema (HAE) show development of atherosclerosis in peripheral blood vessels during symptom-free periods, a new study…